IP Library Granted Patent US 7,173,032
Granted Patent B2
US 7,173,032 · App. 10/390,485 · Granted Feb 6, 2007

Methods and compositions of novel triazine compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,173,032
App. No.
10/390,485
Granted
Feb 6, 2007
Kind
B2
Abstract

The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

Claims (621)

1. A compound selected from:

N 2 -(4-bromo-1-naphthyl)-N 4 -cycloheptyl-N 6 -[(1-ethyl-2-pyrrolidinyl)methyl]-1,3,5-triazine-2,4,6-triamine,

N 2 -(4-chloro-1-naphthyl)-N 4 -cycloheptyl-N 6 -[(1-ethyl-2-pyrrolidinyl)methyl]-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(3-quinolinyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(6-quinolinyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N4-[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(8-quinolinyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -[1-(2-naphthyl)ethyl]-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -(3,4-dichlorophenyl)-N 6 -[(1-ethyl-2-pyrrolidinyl)methyl]-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -(3,4-difluorophenyl)-N 6 -[(1-ethyl-2-pyrrolidinyl)methyl]-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -[4-(trifluoromethoxy)phenyl]-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(4-fluorophenyl)-1,3,5-triazine-2,4,6-triamine,

4-[(4-(cycloheptylamino)-6-{[(1-ethyl-2-pyrrolidinyl)methyl]amino}-1,3,5-triazin-2-yl)-amino]benzonitrile,

N 2 -(4-chlorophenyl)-N 4 -cycloheptyl-N 6 -[(1-ethyl-2-pyrrolidinyl)methyl]-1,3,5-triazine-2,4,6-triamine,

N 2 -(4-bromophenyl)-N 4 -cycloheptyl-N 6 -[(1-ethyl-2-pyrrolidinyl)methyl]-1,3,5-triazine-2,4,6-triamine,

Ethyl 4-[(4-(cycloheptylamino)-6-{[(1-ethyl-2-pyrrolidinyl)methyl]amino}-1,3,5-triazin-2-yl)-amino]benzoate,

N 2 -(1,1′-biphenyl-4-yl)-N 4 -cycloheptyl-N 6 -[(1-ethyl-2-pyrrolidinyl)methyl]-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(3-fluorophenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -(3-chlorophenyl)-N 4 -cycloheptyl-N 6 -[(1-ethyl-2-pyrrolidinyl)methyl]-1,3,5-triazine-2,4,6-triamine,

N 2 -(3-bromophenyl)-N 4 -cycloheptyl-N 6 -[(1-ethyl-2-pyrrolidinyl)methyl]-1,3,5-triazine-2,4,6-triamine,

Ethyl 3-[(4-(cycloheptylamino)-6-{[(1-ethyl-2-pyrrolidinyl)methyl]amino}-1,3,5-triazin-2-yl)-amino]benzoate,

N 2 -cycloheptyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(2-fluorophenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -(2-chlorophenyl)-N 4 -cycloheptyl-N 6 -[(1-ethyl-2-pyrrolidinyl)methyl]-1,3,5-triazine-2,4,6-triamine,

N 2 -(2-bromophenyl)-N 4 -cycloheptyl-N 6 -[(1-ethyl-2-pyrrolidinyl)methyl]-1,3,5-triazine-2,4,6-triamine,

N 2 -(1,3-benzodioxol-5-yl)-N 4 -cycloheptyl-N 6 -[(1-ethyl-2-pyrrolidinyl)methyl]-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -(2,3-dihydro-1,4-benzodioxin-6-yl)-N 6 -[(1-ethyl-2-pyrrolidinyl)methyl]-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -[4-(dimethylamino)phenyl]-N 6 -[(1-ethyl-2-pyrrolidinyl)methyl]-1,3,5-triazine-2,4,6-triamine,

N 2 -[3-chloro-4-(diethylamino)phenyl]-N 4 -cycloheptyl-N 6 -[(1-ethyl-2-pyrrolidinyl)methyl]-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -[4-(4-morpholinyl)phenyl]-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -[4-(4-methyl-1-piperazinyl)phenyl]-1,3,5-triazine-2,4,6-triamine,

N-{4-[(4-(cycloheptylamino)-6-{[(1-ethyl-2-pyrrolidinyl)methyl]amino}-1,3,5-triazin-2-yl)-amino]phenyl}acetamide,

N-{3-[(4-(cycloheptylamino)-6-{[(1-ethyl-2-pyrrolidinyl)methyl]amino}-1,3,5-triazin-2-yl)-amino]phenyl}acetamide,

N 2 -cycloheptyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(3-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -(4-ethoxyphenyl)-N 6 -[(1-ethyl-2-pyrrolidinyl)methyl]-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -[4-(methylthio)phenyl]-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(2-pyridinyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(2-methylphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(4-phenoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(3-methylphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(4-methylphenyl)-1,3,5-triazine-2,4,6-triamine,

2-[(4-(cycloheptylamino)-6-{[(1-ethyl-2-pyrrolidinyl)methyl]amino}-1,3,5-triazin-2-yl)-amino]-4-methyl-3-thiophenecarboxamide,

N 2 -(4-chlorophenyl)-N 4 -cycloheptyl-N 6 -[(11-ethyl-2-pyrrolidinyl)methyl]-N 2 -methyl-1,3,5-triazine-2,4,6-triamine,

3-[(4-(cycloheptylamino)-6-{[(1-ethyl-2-pyrrolidinyl)methyl]amino}-1,3,5-triazin-2-yl)-(phenyl)amino]propanenitrile,

N 2 -cycloheptyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(4-methoxyphenyl)-N 6 -methyl-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -(2,4-difluorophenyl)-N 6 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 4 -methyl-1,3,5-triazine-2,4,6-triamine,

[(4-(cycloheptylamino)-6-{[(1-ethyl-2-pyrrolidinyl)methyl]amino}-1,3,5-triazin-2-yl)(phenyl)amino]acetonitrile,

N 2 -(3-chlorophenyl)-N 4 -cycloheptyl-N 6 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 2 -methyl-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -methyl-N 6 -[2-(trifluoromethyl)phenyl]-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -methyl-N 6 -[4-(trifluoromethoxy)phenyl]-1,3,5-triazine-2,4,6-triamine,

N 2 -(3-chloro-4-methoxyphenyl)-N 4 -cycloheptyl-N 6 -[(1-ethyl-2-pyrrolidinyl)methyl]-1,3,5-triazine-2,4,6-triamine,

N-benzoyl-4-[(4-(cycloheptylamino)-6-{[(1-ethyl-2-pyrrolidinyl)methyl]amino}-1,3,5-triazin-2-yl)-amino]benzenesulfonamide,

N 2 -cycloheptyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(2-naphthyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -ethyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -(tert-butyl)-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -benzyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cyclooctyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cyclohexyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cyclopentyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 4 -(3-fluoro-4-methoxyphenyl)-6-(1-pyrrolidinyl)-1,3,5-triazine-2,4-diamine,

N 2 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 4 -(3-fluoro-4-methoxyphenyl)-N 6 -hexahydro-1H-azepin-1-yl-1,3,5-triazine-2,4-diamine,

N 2 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 4 -(3-fluoro-4-methoxyphenyl)-N 6 -octahydro-1(2H)-quinolinyl-1,3,5-triazine-2,4-diamine,

N 2 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 4 -(3-fluoro-4-methoxyphenyl)-N 6 -(4-methylcyclohexyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -(1-ethyl-pyrrolidin-2-ylmethyl]-N 4 -(3-fluoro-4-methoxyphenyl)-6-((S)-2-methoxymethyl-pyrrolidin-1-yl)-1,3,5-triazine-2,4-diamine,

N 2 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 4 -(3-fluoro-4-methoxyphenyl)-6-(4-methyl-1-piperazinyl)-1,3,5-triazine-2,4-diamine,

6-(4-acetyl-1-piperazinyl)-N 2 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 4 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4-diamine,

Ethyl 4-{4-{[(1-ethyl-2-pyrrolidinyl)methyl]amino}-N 6 -[(3-fluoro-4-methoxyphenyl)amino]-1,3,5-triazin-2-yl}-1-piperazinecarboxylate,

N 2 -(cyclohexylmethyl)-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 4 -(3-fluoro-4-methoxyphenyl)-N 6 -(2-furylmethyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 4 -(3-fluoro-4-methoxyphenyl)-N 6 -(2,2,2-trifluoroethyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -[2-(dimethylamino)ethyl]-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 4 -(3-fluoro-4-methoxyphenyl)-N 6 -{4-[2-oxo-2-(1-pyrrolidinyl)ethyl]-1-piperazinyl}-1,3,5-triazine-2,4-diamine,

N 2 ,N 4 -bis[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 4 -(3-fluoro-4-methoxyphenyl)-N 6 -[2-(1-piperidinyl)ethyl]-1,3,5-triazine-2,4,6-triamine,

N 6 -[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]-N 2 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 4 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4-diamine,

N 2 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 4 -(3-fluoro-4-methoxyphenyl)-N 6 -[4-(2-pyridinyl)-1-piperazinyl]-1,3,5-triazine-2,4-diamine,

1-[3-({4-{[(1-ethyl-2-pyrrolidinyl)methyl]amino}-6-[(3-fluoro-4-methoxyphenyl)amino]-1,3,5-triazin-2-yl}amino)propyl]-2-pyrrolidinone,

N 2 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 4 -(3-fluoro-4-methoxyphenyl)-N 6 -[3-(1H-imidazol-1-yl)propyl]-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -ethyl-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -(tert-butyl)-N 4 -cycloheptyl-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -benzyl-N 4 -cycloheptyl-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -cyclooctyl-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -cyclohexyl-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -cyclopentyl-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -(3-fluoro-4-methoxyphenyl)-6-(1-pyrrolidinyl)-1,3,5-triazine-2,4-diamine,

N 2 -cycloheptyl-N 4 -(3-fluoro-4-methoxyphenyl)-6-hexahydro-1H-azepin-1-yl-1,3,5-triazine-2,4-diamine,

N 2 -cycloheptyl-N 4 -(3-fluoro-4-methoxyphenyl)-6-octahydro-1(2H)-quinolinyl-1,3,5-triazine-2,4-diamine,

N 2 -cycloheptyl-N 4 -(3-fluoro-4-methoxyphenyl)-N 6 -(4-methylcyclohexyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -(3-fluoro-4-methoxyphenyl)-6-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-1,3,5-triazine-2,4-diamine,

N 2 -cycloheptyl-N 4 -(3-fluoro-4-methoxyphenyl)-6-(4-methyl-1-piperazinyl)-1,3,5-triazine-2,4-diamine,

6-(4-acetyl-1-piperazinyl)-N 2 -cycloheptyl-N 4 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4-diamine,

ethyl-4-{4-(cycloheptylamino)-6-[(3-fluoro-4-methoxyphenyl)amino]-1,3,5-triazin-2-yl}-1-piperazinecarboxylate,

N 2 -cycloheptyl-N 4 -(cyclohexylmethyl)-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -(3-fluoro-4-methoxyphenyl)-N 6 -(2-furanylmethyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -(3-fluoro-4-methoxyphenyl)-N 6 -(2,2,2-trifluoroethyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -[2-(dimethylamino)ethyl]-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -(3-fluoro-4-methoxyphenyl)-6-{4-[2-oxo-(1-pyrrolidinyl)ethyl]-1-piperazinyl}-1,3,5-triazine-2,4-diamine,

N 2 -cycloheptyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -(3-fluoro-4-methoxyphenyl)-N 6 -[2-(1-piperidinyl)ethyl]-1,3,5-triazine-2,4,6-triamine,

6-[4-(1,3-benzodioxol-5-ylmethyl)1-piperazinyl]-N 2 -cycloheptyl-N 4 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4-diamine,

N 2 -cycloheptyl-N 4 -(3-fluoro-4-methoxyphenyl)-6-[4-(2-pyridinyl)-1-piperazinyl]-1,3,5-triazine-2,4-triamine,

1-[3-({4-(cycloheptylamino)-6-[(3-fluoro-4-methoxyphenyl)amino]-1,3,5-triazin-2-yl}amino)propyl]-2-pyrrolidinone,

N 2 -cycloheptyl-N 4 -(3-fluoro-4-methoxyphenyl)-N 6 -[3-(1H-imidazol-1-yl)propyl]-1,3,5-triazine-2,4,6-triamine,

(3-Chloro-4-methoxy-phenyl)-(4,6-dichloro-[1,3,5]triazin-2-yl)-amine,

6-Chloro-N-(3-chloro-4-methoxy-phenyl)-N′-cyclohexylmethyl-[1,3,5]triazine-2,4-diamine,

N-(3-Chloro-4-methoxy-phenyl)-N′-cyclohexylmethyl-N″-methyl-N″-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4,6-triamine,

6-Chloro-N-(3-chloro-4-methoxy-phenyl)-N′-(1-propyl-butyl)-[1,3,5]triazine-2,4-diamine,

N-(3-Chloro-4-methoxy-phenyl)-N′-methyl-N′-(1-methyl-piperidin-4-yl)-N″-(1-propyl-butyl)-[1,3,5]triazine-2,4,6-triamine,

N-(3-Chloro-4-methoxy-phenyl)-N′-isopropyl-N″-methyl-N″-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4,6-triamine,

N 2 -(3-chloro-4-methoxy-phenyl)-N 4 -isopropyl-N 6 -methyl-N 6 -piperidin-4-yl-1,3,5-triazine-2,4,6-triamine,

5-{4-(3-Chloro-4-methoxy-phenylamino)-6-[methyl-(1-methyl-piperidin-4-yl)-amino]-[1,3,5]triazin-2-ylamino}-pentan-1-ol,

5-[4-(3-chloro-4-methoxy-phenylamino)-6-(methyl-piperidin-4-yl-amino)-1,3,5-triazin-2-ylamino]-pentan-1-ol,

N-Butyl-6-chloro-N′-(3-chloro-4-methoxy-phenyl)-N-propyl-[1,3,5]triazine-2,4-diamine,

N-Butyl-N′-(3-chloro-4-methoxy-phenyl)-N″-methyl-N″-(1-methyl-piperidin-4-yl)-N-propyl-[1,3,5]triazine-2,4,6-triamine,

N 2 -Butyl-N 4 -(3-chloro-4-methoxy-phenyl)-N 6 -methyl-N 6 -piperidin-4-yl-N 2 -propyl-1,3,5-triazine-2,4,6-triamine,

2,4-Dichloro-6-cyclohexylmethoxy-[1,3,5]triazine,

(4-Chloro-6-cyclohexylmethoxy-[1,3,5]triazin-2-yl)-(3-fluoro-4-methoxy-phenyl)-amine,

6-Cyclohexylmethoxy-N,N′-bis-(3-fluoro-4-methoxy-phenyl)-1,3,5-triazine-2,4-diamine,

6-Cyclohexylmethoxy-N-(1-ethyl-pyrrolidin-2-ylmethyl)-N′-(3-fluoro-4-methoxy-phenyl)-[1,3,5]triazine-2,4-diamine,

(4-Chloro-6-cyclohexylmethoxy-[1,3,5]triazin-2-yl)-(3-chloro-4-methoxy-phenyl)-amine,

N,N′-Bis-(3-chloro-4-methoxy-phenyl)-6-cyclohexylmethoxy-1,3,5-triazine-2,4-diamine,

N-(3-Chloro-4-methoxy-phenyl)-6-cyclohexylmethoxy-N′-methyl-N′-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4-diamine,

6-Chloro-N,N″-bis-(3-chloro-4-methoxy-phenyl)-[1,3,5]triazine-2,4-diamine,

N,N′-Bis-(3-chloro-4-methoxy-phenyl)-N″-methyl-N″-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4,6-triamine,

N,N′-Bis-(3-chloro-4-methoxy-phenyl)-N″-cycloheptyl-[1,3,5]triazine-2,4,6-triamine,

N-(3-Bromo-4-methoxy-phenyl)-N′-cycloheptyl-N″-methyl-N″-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4,6-triamine,

(4,6-Dichloro-[1,3,5]triazin-2-yl)-(3-fluoro-4-methoxy-phenyl)-amine,

6-Chloro-N-cyclohexylmethyl-N′-(3-fluoro-4-methoxy-phenyl)-[1,3,5]triazine-2,4-diamine,

N-Cyclohexylmethyl-N′-(1-ethyl-pyrrolidin-2-ylmethyl)-N″-(3-fluoro-4-methoxy-phenyl)-[1,3,5]triazine-2,4,6-triamine,

6-Chloro-N-cycloheheptyl-N′-(3-fluoro-4-methoxy-phenyl)-[1,3,5]triazine-2,4-diamine,

N-Cycloheptyl-N′-(3-fluoro-4-methoxy-phenyl)-6-pyrrolidin-1-yl-[1,3,5]triazine-2,4-diamine,

N-Cycloheptyl-N′-ethyl-N″-(3-fluoro-4-methoxy-phenyl)-[1,3,5]triazine-2,4-diamine,

N-Cycloheptyl-N′-(1-ethyl-pyrrolidin-2-ylmethyl)-N″-(3-fluoro-4-methoxy-phenyl)-[1,3,5]triazine-2,4,6-triamine,

2-[4-chloro-6-(3-chloro-4-methoxy-phenylamino)-[1,3,5]triazin-2-ylamino]-propane-1,3-diol,

2-{4-(3-chloro-4-methoxy-phenylamino)-6-[methyl-(1-methyl-piperidin-4-yl)-amino]-[1,3,5]triazin-2-ylamino}-propane-1,3-diol,

6-Chloro-N-(3-chloro-4-methoxy-phenyl)-N′-cycloheptyl-[1,3,5]triazine-2,4-diamine,

N-(1-benzyl-piperidin-4-yl)-N′-(3-chloro-4-methoxy-phenyl)-N″-cycloheptyl-[1,3,5]-2,4,6-triamine,

N 2 -(3-chloro-4-methoxy-phenyl)-N 4 -cycloheptyl-N 6 -piperidin-4-yl-1,3,5-triazine-2,4,6-triamine,

N 2 -(3-chloro-4-methoxy-phenyl)-N 4 -cycloheptyl-N 6 -(1-ethyl-pyrrolidin-2-ylmethyl)-1,3,5-triazine-2,4,6-triamine,

N-(3-Chloro-4-methoxy-phenyl)-N′-cycloheptyl-N′-methyl-N″-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4,6-triamine,

2-chloro-4-{4-cycloheptylamino-6-[methyl-(1-methyl-piperidin-4-yl-amino]-1,3,5-triazin-2-ylamino}-phenol,

N 2 -cycloheptyl-N 4 -((S)-1-ethyl-pyrrolidin-2-ylmethyl)-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -((R)-1-ethyl-pyrrolidin-2-ylmethyl)-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cyclohexylmethyl-N 4 -((S)-1-ethyl-pyrrolidin-2-ylmethyl)-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cyclohexylmethyl-N 4 -((R)-1-ethyl-pyrrolidin-2-ylmethyl)-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

({4-cycloheptylamino-6-[((S)-1-ethyl-pyrrolidin-2-ylmethyl)-amino]-1,3,5-triazin-2-yl}-phenyl-amino)-acetonitrile,

({4-cycloheptylamino-6-[((R)-1-ethyl-pyrrolidin-2-ylmethyl)-amino]-1,3,5-triazin-2-yl}-phenyl-amino)-acetonitrile,

N 2 -[(1-ethyl-2-pyrrolidinyl]-N 4 -(3-fluoro-4-methoxyphenyl)-6-[(S)-2-(methoxymethyl)-1-pyrrolidinyl]-1,3,5-triazine-2,4-diamine,

N 2 -(3-chloro-4-methoxy-phenyl)-N 4 -cycloheptyl-N 6 -methyl-N 6 -piperidin-4-yl-1,3,5-triazine-2,4,6-triamine,

4-(3-Chloro-4-methoxy-phenylamino)-6-cycloheptylamino-1,3,5-triazin-2-ol,

N-(1-Aza-bicyclo[2.2.2]oct-3-yl)-N′-(3-chloro-4-methoxy-phenyl)-N″-) 1-ethyl-pyrrolidin-2-ylmethyl)-[1,3,5]triazine-2,4,6-triamine,

N 2 -(3-chloro-4-diethylamino-phenyl)-N 4 -cycloheptyl-N 6 -(1-ethyl-pyrrolidin-2-ylmethyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -(2-dimethylamino-ethyl)-N 6 -(3-fluoro-4-methoxy-phenyl)-1,3,5-triazine-2,4,6-triamine,

({4-cycloheptylamino-6-[1-ethyl-pyrrolidin-2-ylmethyl)-amino]-1,3,5-triazin-2-yl}-phenyl-amino)-acetonitrile,

N-Azepan-1-yl-6-chloro-N′-(3-chloro-4-methoxy-phenyl)-[1,3,5]triazine-2,4-diamine,

N″-(3-chloro-4-methoxy-phenyl)-N,N′-bis-perhydro-azepin-1-yl-1,3,5-triazine-2,4,6-triamine,

N-Azepan-1-yl-N′-(3-chloro-4-methoxy-phenyl)-N″-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4,6-triamine,

N 4 -(3-chloro-4-methoxy-phenyl)-N 6 -methyl-N 2 -perhydro-azepin-1-yl-N 6 -piperidin-4-yl-1,3,5-triazine-2,4,6-triamine,

N,N′-di-n-propyl-N″-(3-fluoro-4-methoxy-phenyl)-1,3,5-triazine-2,4,6-triamine,

N,N′-dicyclopropyl-N″-(3-fluoro-4-methoxy-phenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -Cycloheptyl-N 4 -(3-fluoro-4-methoxy-phenyl)-N 6 -methyl-N 6 -(1-methyl-piperidin-4-yl)-1,3,5-triazine-2,4,6-triamine,

N 2 -Cycloheptyl-N 4 -(3-fluoro-4-methoxy-phenyl)-N 6 -methyl-N 6 -piperidin-4-yl-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -(3-fluoro-4-methoxyphenyl)-N 6 -methyl-N 6 -(1-methyl-piperidin-4-yl)-1,3,5-triazine-2,4,6-triamine, hydrogen chloride salt,

[N-(3-Chloro-4-methoxy-phenyl)-N′-cycloheptyl-N″-methyl-N″-(1-methyl-piperidin-4-yl)-[1,3,5]trizaine-2,4,6-triamine, hydrogen chloride salt,

N 2 -(3-chloro-4-diethylamino-phenyl)-N 4 -cycloheptyl-N 6 -(1-ethyl-pyrrolidin-2-ylmethyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -(3-chloro-4-diethylamino-phenyl)-N 4 -cycloheptyl-N 6 -(1-ethyl-pyrrolidin-2-ylmethyl)-1,3,5-triazine-2,4,6-triamine hydrogen chloride salt,

N 2 -cycloheptyl-N 4 -(1-ethyl-pyrrolidin-2-ylmethyl)-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine hydrogen chloride salt,

N 2 -(cyclohexylmethyl)-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(4-fluoro-3-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine hydrogen chloride salt,

({4-cycloheptylamino-6-[(1-ethyl-pyrrolidin-2-ylmethyl)-amino]-1,3,5-triazin-2-yl}-phenyl-amino)-acetonitrile hydrogen chloride salt,

N 2 -cycloheptyl-N 4 -(3-fluoro-4-methoxy-phenyl)-N 6 -methyl-N 6 -(1-methyl-piperidin-4-yl)-1,3,5-triazine-2,4,6-triamine maleate salt,

N 2 -cycloheptyl-N 4 -(3-fluoro-4-methoxy-phenyl)-N 6 -methyl-N 6 -(1-methyl-piperidin-4-yl)-1,3,5-triazine-2,4,6-triamine citrate salt,

N 2 -cycloheptyl-N 4 -(3-fluoro-4-methoxy-phenyl)-N 6 -methyl-N 6 -(1-methyl-piperidin-4-yl)-1,3,5-triazine-2,4,6-triamine succinate salt, or

N-(3-Bromo-4-methoxy-phenyl)-N′-cycloheptyl-N″-methyl-N″-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4,6-triamine hydrogen chloride salt.

2. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound selected from:

N 2 -(4-bromo-1-naphthyl)-N 4 -cycloheptyl-N 6 -[(1-ethyl-2-pyrrolidinyl)methyl]-1,3,5-triazine-2,4,6-triamine,

N 2 -(4-chloro-1-naphthyl)-N 4 -cycloheptyl-N 6 -[(1-ethyl-2-pyrrolidinyl)methyl]-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(3-quinolinyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(6-quinolinyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(8-quinolinyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -[1-(2-naphthyl)ethyl]-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -(3,4-dichlorophenyl)-N 6 -[(1-ethyl-2-pyrrolidinyl)methyl]-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -(3,4-difluorophenyl)-N 6 -[(1-ethyl-2-pyrrolidinyl)methyl]-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -[4-(trifluoromethoxy)phenyl]-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(4-fluorophenyl)-1,3,5-triazine-2,4,6-triamine,

4-[(4-(cycloheptylamino)-6-{[(1-ethyl-2-pyrrolidinyl)methyl]amino}-1,3,5-triazin-2-yl)-amino]benzonitrile,

N 2 -(4-chlorophenyl)-N 4 -cycloheptyl-N 61 -[(1-ethyl-2-pyrrolidinyl)methyl]-1,3,5-triazine-2,4,6-triamine,

N 2 -(4-bromophenyl)-N 4 -cycloheptyl-N 6 -[(1-ethyl-2-pyrrolidinyl)methyl]-1,3,5-triazine-2,4,6-triamine,

Ethyl 4-[(4-(cycloheptylamino)-6-{[(1-ethyl-2-pyrrolidinyl)methyl]amino}-1,3,5-triazin-2-yl)-amino]benzoate,

N 2 -(1,1′-biphenyl-4-yl)-N 4 -cycloheptyl-N 6 -[(1-ethyl-2-pyrrolidinyl)methyl]-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(3-fluorophenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -(3-chlorophenyl)-N 4 -cycloheptyl-N 6 -[(1-ethyl-2-pyrrolidinyl)methyl]-1,3,5-triazine-2,4,6-triamine,

N 2 -(3-bromophenyl)-N 4 -cycloheptyl-N 6 -[(1-ethyl-2-pyrrolidinyl)methyl]-1,3,5-triazine-2,4,6-triamine,

Ethyl 3-[(4-(cycloheptylamino)-6-{[(1-ethyl-2-pyrrolidinyl)methyl]amino}-1,3,5-triazin-2-yl)-amino]benzoate,

N 2 -cycloheptyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(2-fluorophenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -(2-chlorophenyl)-N 4 -cycloheptyl-N 6 -[(1-ethyl-2-pyrrolidinyl)methyl]-1,3,5-triazine-2,4,6-triamine,

N 2 -(2-bromophenyl)-N 4 -cycloheptyl-N 6 -[(1-ethyl-2-pyrrolidinyl)methyl]-1,3,5-triazine-2,4,6-triamine,

N 2 -(1,3-benzodioxol-5-yl)-N 4 -cycloheptyl-N 6 -[(1-ethyl-2-pyrrolidinyl)methyl]-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -(2,3-dihydro-1,4-benzodioxin-6-yl)-N 6 -[(1-ethyl-2-pyrrolidinyl)methyl]-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -[4-(dimethylamino)phenyl]-N 6 -[(1-ethyl-2-pyrrolidinyl)methyl]-1,3,5-triazine-2,4,6-triamine,

N 2 -[3-chloro-4-(diethylamino)phenyl]-N 4 -cycloheptyl-N 6 -[(1-ethyl-2-pyrrolidinyl)methyl]-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -[4-(4-morpholinyl)phenyl]-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -[4-(4-methyl-1-piperazinyl)phenyl]-1,3,5-triazine-2,4,6-triamine,

N-{4-[(4-(cycloheptylamino)-6-{[(1-ethyl-2-pyrrolidinyl)methyl]amino}-1,3,5-triazin-2-yl)-amino]phenyl}acetamide,

N-{3-[(4-(cycloheptylamino)-6-{[(1-ethyl-2-pyrrolidinyl)methyl]amino}-1,3,5-triazin-2-yl)-amino]phenyl}acetamide,

N 2 -cycloheptyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(3-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -(4-ethoxyphenyl)-N 6 -[(1-ethyl-2-pyrrolidinyl)methyl]-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -[4-(methylthio)phenyl]-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(2-pyridinyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(2-methylphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(4-phenoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(3-methylphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(4-methylphenyl)-1,3,5-triazine-2,4,6-triamine,

2-[(4-(cycloheptylamino)-6-{[(1-ethyl-2-pyrrolidinyl)methyliamino}-1,3,5-triazin-2-yl)-amino]-4-methyl-3-thiophenecarboxamide,

N 2 -(4-chlorophenyl)-N 4 -cycloheptyl-N 6 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 2 -methyl-1,3,5-triazine-2,4,6-triamine,

3-[(4-(cycloheptylamino)-6-{[(1-ethyl-2-pyrrolidinyl)methyl]amino}-1,3,5-triazin-2-yl)-(phenyl)amino]propanenitrile,

N 2 -cycloheptyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(4-methoxyphenyl)-N 6 -methyl-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -(2,4-difluorophenyl)-N 6 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 4 -methyl-1,3,5-triazine-2,4,6-triamine,

[(4-(cycloheptylamino)-6-{[(1-ethyl-2-pyrrolidinyl)methyl]amino}-1,3,5-triazin-2-yl)(phenyl)amino]acetonitrile,

N 2 -(3-chlorophenyl)-N 4 -cycloheptyl-N 6 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 2 -methyl-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -methyl-N 6 -[2-(trifluoromethyl)phenyl]-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -methyl-N 6 -[4-(trifluoromethoxy)phenyl]-1,3,5-triazine-2,4,6-triamine,

N 2 -(3-chloro-4-methoxyphenyl)-N 4 -cycloheptyl-N 6 -[(1-ethyl-2-pyrrolidinyl)methyl]-1,3,5-triazine-2,4,6-triamine,

N-benzoyl-4-[(4-(cycloheptylamino)-6-{[(1-ethyl-2-pyrrolidinyl)methyl]amino}-1,3,5-triazin-2-yl)-amino]benzenesulfonamide,

N 2 -cycloheptyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(2-naphthyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -ethyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -(tert-butyl)-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -benzy]-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cyclooctyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cyclohexyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cyclopentyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 4 -(3-fluoro-4-methoxyphenyl)-6-(1-pyrrolidinyl)-1,3,5-triazine-2,4-diamine,

N 2 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 4 -(3-fluoro-4-methoxyphenyl)-N 6 -hexahydro-1H-azepin-1-yl-1,3,5-triazine-2,4-diamine,

N 2 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 4 -(3-fluoro-4-methoxyphenyl)-N 6 -octahydro-1(2H)-quinolinyl-1,3,5-triazine-2,4-diamine,

N 2 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 4 -(3-fluoro-4-methoxyphenyl)-N 6 -(4-methylcyclohexyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -(1-ethyl-pyrrolidin-2-ylmethyl]-N 4 -(3-fluoro-4-methoxyphenyl)-6-((S)-2-methoxymethyl-pyrrolidin-1-yl)-1,3,5-triazine-2,4-diamine,

N 2 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 4 -(3-fluoro-4-methoxyphenyl)-6-(4-methyl-1-piperazinyl)-1,3,5-triazine-2,4-diamine,

6-(4-acetyl-1-piperazinyl)-N 2 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 4 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4-diamine,

Ethyl 4-{4-{[(1-ethyl-2-pyrrolidinyl)methyl]amino}-N 6 -[(3-fluoro-4-methoxyphenyl)amino]-1,3,5-triazin-2-yl}-1-piperazinecarboxylate,

N 2 -(cyclohexylmethyl)-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 4 -(3-fluoro-4-methoxyphenyl)-N 6 -(2-furylmethyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 4 -(3-fluoro-4-methoxyphenyl)-N 6 -(2,2,2-trifluoroethyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -[2-(dimethylamino)ethyl]-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 4 -(3-fluoro-4-methoxyphenyl)-N 6 -{4-[2-oxo-2-(1-pyrrolidinyl)ethyl]-1-piperazinyl}-1,3,5-triazine-2,4-diamine,

N 2 ,N 4 -bis[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 4 -(3-fluoro-4-methoxyphenyl)-N 6 -[2-(1-piperidinyl)ethyl]-1,3,5-triazine-2,4,6-triamine,

N 6 -[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]-N 2 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 4 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4-diamine,

N 2 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 4 -(3-fluoro-4-methoxyphenyl)-N 6 -[4-(2-pyridinyl)-1-piperazinyl]-1,3,5-triazine-2,4-diamine,

1-[3-({4-{[(1-ethyl-2-pyrrolidinyl)methyl]amino}-6-[(3-fluoro-4-methoxyphenyl)amino]-1,3,5-triazin-2-yl}amino)propyl]-2-pyrrolidinone,

N 2 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 4 -(3-fluoro-4-methoxyphenyl)-N 6 -[3-(1H-imidazol-1-yl)propyl]-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -ethyl-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -(tert-butyl)-N 4 -cycloheptyl-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -benzyl-N 4 -cycloheptyl-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -cyclooctyl-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -cyclohexyl-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -cyclopentyl-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -(3-fluoro-4-methoxyphenyl)-6-(1-pyrrolidinyl)-1,3,5-triazine-2,4-diamine,

N 2 -cycloheptyl-N 4 -(3-fluoro-4-methoxyphenyl)-6-hexahydro-1H-azepin-1-yl-1,3,5-triazine-2,4-diamine,

N 2 -cycloheptyl-N 4 -(3-fluoro-4-methoxyphenyl)-6-octahydro-1(2H)-quinolinyl-1,3,5-triazine-2,4-diamine,

N 2 -cycloheptyl-N 4 -(3-fluoro-4-methoxyphenyl)-N 6 -(4-methylcyclohexyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -(3-fluoro-4-methoxyphenyl)-6-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-1,3,5-triazine-2,4-diamine,

N 2 -cycloheptyl-N 4 -(3-fluoro-4-methoxyphenyl)-6-(4-methyl-1-piperazinyl)-1,3,5-triazine-2,4-diamine,

6-(4-acetyl-1-piperazinyl)-N 2 -cycloheptyl-N 4 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4-diamine,

ethyl-4-{4-(cycloheptylamino)-6-[(3-fluoro-4-methoxyphenyl)amino]-1,3,5-triazin-2-yl}-1-piperazinecarboxylate,

N 2 -cycloheptyl-N 4 -(cyclohexylmethyl)-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -(3-fluoro-4-methoxyphenyl)-N 6 -(2-furanylmethyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -(3-fluoro-4-methoxyphenyl)-N 6 -(2,2,2-trifluoroethyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -[2-(dimethylamino)ethyl]-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cyclobepty-N 4 -(3-fluoro-4-methoxyphenyl)-6-{4-[2-oxo-(1-pyrrolidinyl)ethyl]-1-piperazinyl}-1,3,5-triazine-2,4-diamine,

N 2 -cycloheptyl-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -(3-fluoro-4-methoxyphenyl)-N 6 -[2-(1-piperidinyl)ethyl]-1,3,5-triazine-2,4,6-triamine,

6-[4-(1,3-benzodioxol-5-ylmethyl)1-piperazinyl]-N 2 -cycloheptyl-N 4 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4-diamine,

N 2 -cycloheptyl-N 4 -(3-fluoro-4-methoxyphenyl)-6-[4-(2-pyridinyl)-1-piperazinyl]-1,3,5-triazine-2,4-triamine,

1-[3-({4-(cycloheptylamino)-6-[(3-fluoro-4-methoxyphenyl)amino]-1,3,5-triazin-2-yl}amino)propyl]-2-pyrrolidinone,

N 2 -cycloheptyl-N 4 -(3-fluoro-4-methoxyphenyl)-N 6 -[3-(1H-imidazol-1-yl)propyl]-1,3,5-triazine-2,4,6-triamine,

(3-Chloro-4-methoxy-phenyl)-(4,6-dichloro-[1,3,S]triazin-2-yl)-amine,

6-Chloro-N-(3-chloro-4-methoxy-phenyl)-N′-cyclohexylmethyl-[1,3,5]triazine-2,4-diamine,

N-(3-Chloro-4-methoxy-phenyl)-N′-cyclohexylmethyl-N″-methyl-N″-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4,6-triamine,

6-Chloro-N-(3-chloro-4-methoxy-phenyl)-N′-(1-propyl-butyl)-[1,3,5]triazine-2,4-diamine,

N-(3-Chloro-4-methoxy-phenyl)-N′-methyl-N′-(1-methyl-piperidin-4-yl)-N″-(1-propyl-butyl)-[1,3,5]triazine-2,4,6-triamine,

N-(3-Chloro-4-methoxy-phenyl)-N′-isopropyl-N″-methyl-N″-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4,6-triamine,

N 2 -(3-chloro-4-methoxy-phenyl)-N 4 -isopropyl-N 6 -methyl-N 6 -piperidin-4-yl-1,3,5-triazine-2,4,6-triamine,

5-{4-(3-Chloro-4-methoxy-phenylamino)-6-[methyl-(1-methyl-piperidin-4-yl)-amino]-[1,3,5]triazin-2-ylamino}-pentan-1-ol,

5-[4-(3-chloro-4-methoxy-phenylamino)-6-(methyl-piperidin-4-yl-amino)-1,3,5-triazin-2-ylamino]-pentan-1-ol,

N-Butyl-6-chloro-N′-(3-chloro-4-methoxy-phenyl)-N-propyl-[1,3,5]triazine-2,4-diamine,

N-Butyl-N′-(3-chloro-4-methoxy-phenyl)-N″-methyl-N″-(1-methyl-piperidin-4-yl)-N-propyl-[1,3,5]triazine-2,4,6-triamine,

N 2 -Butyl-N 4 -(3-chloro-4-methoxy-phenyl)-N 6 -methyl-N 6 -piperidin-4-yl-N 2 -propyl-1,3,5-triazine-2,4,6-triamine,

2,4-Dichloro-6-cyclohexylmethoxy-[1,3,5]triazine,

(4-Chloro-6-cyclohexylmethoxy-[1,3,5]triazin-2-yl)-(3-fluoro-4-methoxy-phenyl)-amine,

6-Cyclohexylmethoxy-N,N′-bis-(3-fluoro-4-methoxy-phenyl)-1,3,5-triazine-2,4-diamine,

6-Cyclohexylmethoxy-N-(1-ethyl-pyrrolidin-2-ylmethyl)-N′-(3-fluoro-4-methoxy-phenyl)-[1,3,5]triazine-2,4-diamine,

(4-Chloro-6-cyclohexylmethoxy-[1,3,5]triazin-2-yl)-(3-chloro-4-methoxy-phenyl)-amine,

N,N′-Bis-(3-chloro-4-methoxy-phenyl)-6-cyclohexylmethoxy-1,3,5-triazine-2,4-diamine,

N-(3-Chloro-4-methoxy-phenyl)-6-cyclohexylmethoxy-N′-methyl-N′-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4-diamine,

6-Chloro-N,N″-bis-(3-chloro-4-methoxy-phenyl)-[1,3,5]triazine-2,4-diamine,

N,N′-Bis-(3-chloro-4-methoxy-phenyl)-N″-methyl-N″-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4,6-triamine,

N,N′-Bis-(3-chloro-4-methoxy-phenyl)-N″-cycloheptyl-[1,3,5]triazine-2,4,6-triamine,

N-(3-Bromo-4-methoxy-phenyl)-N′-cycloheptyl-N″-methyl-N″-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4,6-triamine,

(4,6-Dichloro-[1,3,5]triazin-2-yl)-(3-fluoro-4-methoxy-phenyl)-amine,

6-Chloro-N-cyclohexylmethyl-N′-(3-fluoro-4-methoxy-phenyl)-[1,3,5]triazine-2,4-diamine,

N-Cyclohexylmethyl-N′-(1-ethyl-pyrrolidin-2-ylmethyl)-N″-(3-fluoro-4-methoxy-phenyl)-[1,3,5]triazine-2,4,6-triamine,

6-Chloro-N-cycloheheptyl-N′-(3-fluoro-4-methoxy-phenyl)-[1,3,5]triazine-2,4-diamine,

N-Cycloheptyl-N′-(3-fluoro-4-methoxy-phenyl)-6-pyrrolidin-1-yl-[1,3,5]triazine-2,4-diamine,

N-Cycloheptyl-N′-ethyl-N″-(3-fluoro-4-methoxy-phenyl)-[1,3,5]triazine-2,4-diamine,

N-Cycloheptyl-N′-(1-ethyl-pyrrolidin-2-ylmethyl)-N″-(3-fluoro-4-methoxy-phenyl)-[1,3,5]triazine-2,4,6-triamine,

2-[4-chloro-6-(3-chloro-4-methoxy-phenylamino)-[1,3,5]triazin-2-ylamino]-propane-1,3-diol,

2-{4-(3-chloro-4-methoxy-phenylamino)-6-[methyl-(1-methyl-piperidin-4-yl)-amino]-[1,3,5]triazin-2-ylamino}-propane-1,3-diol,

6-Chloro-N-(3-chloro-4-methoxy-phenyl)-N′-cycloheptyl-[1,3,5]triazine-2,4-diamine,

N-(1-benzyl-piperidin-4-yl)-N′-(3-chloro-4-methoxy-phenyl)-N″-cycloheptyl-[1,3,5]-2,4,6-triamine,

N 2 -(3-chloro-4-methoxy-phenyl)-N 4 -cycloheptyl-N 6 -piperidin-4-yl-1,3,5-triazine-2,4,6-triamine,

N 2 -(3-chloro-4-methoxy-phenyl)-N 4 -cycloheptyl-N 6 -(1-ethyl-pyrrolidin-2-ylmethyl)-1,3,5-triazine-2,4,6-triamine,

N-(3-Chloro-4-methoxy-phenyl)-N′-cycloheptyl-N″-methyl-N″-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4,6-triamine,

2-chloro-4-{4-cycloheptylamino-6-[methyl-(1-methyl-piperidin-4-yl-amino]-1,3,5-triazin-2-ylamino}-phenol,

N 2 -cycloheptyl-N 4 -((S)-1-ethyl-pyrrolidin-2-ylmethyl)-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -((R)-1-ethyl-pyrrolidin-2-ylmethyl)-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cyclohexylmethyl-N 4 -((S)-1-ethyl-pyrrolidin-2-ylmethyl)-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cyclohexylmethyl-N 4 -((R)-1-ethyl-pyrrolidin-2-ylmethyl)-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine,

({4-cycloheptylamino-6-[((S)-1-ethyl-pyrrolidin-2-ylmethyl)-amino]-1,3,5-triazin-2-yl}-phenyl-amino)-acetonitrile,

({4-cycloheptylamino-6-[((R)-1-ethyl-pyrrolidin-2-ylmethyl)-amino]-1,3,5-triazin-2-yl}-phenyl-amino)-acetonitrile,

N 2 -[(1-ethyl-2-pyrrolidinyl]-N 4 -(3-fluoro-4-methoxyphenyl)-6-[(S)-2-(methoxymethyl)-1-pyrrolidinyl]-1,3,5-triazine-2,4-diamine,

N 2 -(3-chloro-4-methoxy-phenyl)-N 4 -cycloheptyl-N 6 -methyl-N 6 -piperidin-4-yl-1,3,5-triazine-2,4,6-triamine,

4-(3-Chloro-4-methoxy-phenylamino)-6-cycloheptylamino-1,3,5-triazin-2-ol,

N-(1-Aza-bicyclo[2.2.2]oct-3-yl)-N′-(3-chloro-4-methoxy-phenyl)-N′″-)1-ethyl-pyrrolidin-2-ylmethyl)-[1,3,5]triazine-2,4,6-triamine,

N 2 -(3-chloro-4-diethylamino-phenyl)-N 4 -cycloheptyl-N 6 -(1-ethyl-pyrrolidin-2-ylmethyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -(2-dimethylamino-ethyl)-N 6 -(3-fluoro-4-methoxy-phenyl)-1,3,5-triazine-2,4,6-triamine,

({4-cycloheptylamino-6-[1-ethyl-pyrrolidin-2-ylmethyl)-amino]-1,3,5-triazin-2-yl}-phenyl-amino)-acetonitrile,

N-Azepan-1-yl-6-chloro-N′-(3-chloro-4-methoxy-phenyl)-[1,3,5]triazine-2,4-diamine,

N″-(3-chloro-4-methoxy-phenyl)-N,N′-bis-perhydro-azepin-1-yl-1,3,5-triazine-2,4,6-triamine,

N-Azepan-1-yl-N′-(3-chloro-4-methoxy-phenyl)-N″-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4,6-triamine,

N 4 -(3-chloro-4-methoxy-phenyl)-N 6 -methyl-N 2 -perhydro-azepin-1-yl-N 6 -piperidin-4-yl-1,3,5-triazine-2,4,6-triamine,

N,N′-di-n-propyl-N″-(3-fluoro-4-methoxy-phenyl)-1,3,5-triazine-2,4,6-triamine,

N,N′-dicyclopropyl-N″-(3-fluoro-4-methoxy-phenyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -Cycloheptyl-N 4 -(3-fluoro-4-methoxy-phenyl)-N 6 -methyl-N 6 -(1-methyl-piperidin-4-yl)-1,3,5-triazine-2,4,6-triamine,

N 2 -Cycloheptyl-N 4 -(3-fluoro-4-methoxy-phenyl)-N 6 -methyl-N 6 -piperidin-4-yl-1,3,5-triazine-2,4,6-triamine,

N 2 -cycloheptyl-N 4 -(3-fluoro-4-methoxyphenyl)-N 6 -methyl-N 6 -(1-methyl-piperidin-4-yl)-1,3,5-triazine-2,4,6-triamine, hydrogen chloride salt,

[N-(3-Chloro-4-methoxy-phenyl)-N′-cycloheptyl-N″-methyl-N″-(1-methyl-piperidin-4-yl)-[1,3,5]trizaine-2,4,6-triamine, hydrogen chloride salt,

N 2 -(3-chloro-4-diethylamino-phenyl)-N 4 -cycloheptyl-N 6 -(1-ethyl-pyrrolidin-2-ylmethyl)-1,3,5-triazine-2,4,6-triamine,

N 2 -(3-chloro-4-diethylamino-phenyl)-N 4 -cycloheptyl-N 6 -(1-ethyl-pyrrolidin-2-ylmethyl)-1,3,5-triazine-2,4,6-triamine hydrogen chloride salt,

N 2 -cycloheptyl-N 4 -(1-ethyl-pyrrolidin-2-ylmethyl)-N 6 -(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine hydrogen chloride salt,

N 2 -(cyclohexylmethyl)-N 4 -[(1-ethyl-2-pyrrolidinyl)methyl]-N 6 -(4-fluoro-3-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine hydrogen chloride salt,

({4-cycloheptylamino-6-[(1-ethyl-pyrrolidin-2-ylmethyl)-amino]-1,3,5-triazin-2-yl}-phenyl-amino)-acetonitrile hydrogen chloride salt,

N 2 -cycloheptyl-N 4 -(3-fluoro-4-methoxy-phenyl)-N 6 -methyl-N 6 -(1-methyl-piperidin-4-yl)-1,3,5-triazine-2,4,6-triamine maleate salt,

N 2 -cycloheptyl-N 4 -(3-fluoro-4-methoxy-phenyl)-N 6 -methyl-N 6 -(1-methyl-piperidin-4-yl)-1,3,5-triazine-2,4,6-triamine citrate salt,

N 2 -cycloheptyl-N 4 -(3-fluoro-4-methoxy-phenyl)-N 6 -methyl-N 6 -(1-methyl-piperidin-4-yl)-1,3,5-triazine-2,4,6-triamine succinate salt, or

N-(3-Bromo-4-methoxy-phenyl)-N′-cycloheptyl-N″-methyl-N″-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4,6-triamine hydrogen chloride salt.

3. The pharmaceutical composition as claimed in claim 2 , further comprising at least on of the following:

a pharmaceutically acceptable auxiliary;

a pharmaceutically acceptable preservative;

a pharmaceutically acceptable excipient; or

any combination thereof.

4. The pharmaceutical composition as claimed in claim 2 , wherein the pharmaceutical composition is in the form of a tablet, a capsule, a cachet, a powder, a granule, a solution, a suspension, an emulsion, a bolus, a lozenge, a suppository, a pessary, a tampon, a cream, a gel, a paste, a foam, a spray, an aerosol, a microcapsule, a liposome, a transdermal patch, a pastille, a paste, or a mouthwash.

5. A pharmaceutical composition comprising a pharmaceutical acceptable carrier and a compound selected from:

N-Cycloheptyl-N′-methyl-N′-(1-methyl-piperidin-4-yl)-N″-naphthalen-2-yl-[1,3,5]triazine-2,4,6-triamine;

N-Cycloheptyl-N′-(3-fluoro-4-methoxy-phenyl)-N″-methyl-N″-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4,6-triamine;

[4-(4-Benzyl-piperazin-1-yl)-6-morpholin-4-yl-[1,3,5]triazin-2-yl]-(4-methoxy-phenyl)-amine;

N-Cycloheptyl-6-morpholin-4-yl-N′-naphthalen-2-yl-[1,3,5]triazine-2,4-diamine;

N-Cycloheptyl-N′-(3-fluoro-4-methoxy-phenyl)-6-morpholin-4-yl-[1,3,5]triazine-2,4-diamine;

N-Cycloheptyl-6-morpholin-4-yl-N′-phenyl-[1,3,5]triazine-2,4-diamine;

N-Cycloheptyl-N′-(4-methoxy-phenyl)-6-morpholin-4-yl-[1,3,5]triazine-2,4-diamine;

N-Benzyl-N′-cycloheptyl-N″-(4-methoxy-phenyl)-N-methyl-[1,3,5]triazine-2,4,6-triamine;

N-(2-[1,3]Dioxolan-2-yl-ethyl)-N′-methyl-N′-(1-methyl-piperidin-4-yl)-N″-naphthalen-2-yl-[1,3,5]triazine-2,4,6-triamine;

N-Cyclopropyl-N′-methyl-N′-(1-methyl-piperidin-4-yl)-N″-naphthalen-2-yl-[1,3,5]triazine-2,4,6-triamine, or a stereoisomer thereof, a salt thereof, any combination thereof.

6. The pharmaceutical composition as claimed in claim 5 , further comprising at least on of the following:

a pharmaceutically acceptable auxiliary;

a pharmaceutically acceptable preservative;

a pharmaceutically acceptable excipient; or any combination thereof.

7. The pharmaceutical composition as claimed in claim 5 , wherein the pharmaceutical composition is in the form of a tablet, a capsule, a cachet, a powder, a granule, a solution, a suspension, an emulsion, a bolus, a lozenge, a suppository, a pessary, a tampon, a cream, a gel, a paste, a foam, a spray, an aerosol, a microcapsule, a liposome, a transdermal patch, a pastille, a paste, or a mouthwash.

8. A compound of the formula

or a stereoisomer thereof, or a salt thereof, wherein C is selected from

9. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to claim 8 .

10. The pharmaceutical composition according to claim 9 , further comprising at least one of the following:

a pharmaceutically acceptable auxiliary;

a pharmaceutically acceptable preservative;

a pharmaceutically acceptable excipient; or

any combination thereof.

11. The pharmaceutical composition according to claim 9 , wherein the pharmaceutical composition is in the form of a tablet, a capsule, a cachet, a powder, a granule, a solution, a suspension, an emulsion, a bolus, a lozenge, a suppository, a pessary, a tampon, a cream, a gel, a paste, a foam, a spray, an aerosol, a microcapsule, a liposome, a transdermal patch, a pastille, a paste, or a mouthwash.

12. A compound of the formula

or a stereoisomer thereof, or a salt thereof, wherein A and B are independently selected from

13. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to claim 12 .

14. The pharmaceutical composition according to claim 13 , further comprising at least one of the following:

a pharmaceutically acceptable auxiliary;

a pharmaceutically acceptable preservative;

a pharmaceutically acceptable excipient; or

any combination thereof.

15. The pharmaceutical composition according to claim 13 , wherein the pharmaceutical composition is in the form of a tablet, a capsule, a cachet, a powder, a granule, a solution, a suspension, an emulsion, a bolus, a lozenge, a suppository, a pessary, a tampon, a cream, a gel, a paste, a foam, a spray, an aerosol, a microcapsule, a liposome, a transdermal patch, a pastille, a paste, or a mouthwash.

16. A compound of the formula

or a stereoisomer thereof, or a salt thereof, wherein A is selected from

17. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to claim 16 .

18. The pharmaceutical composition according to claim 17 , further comprising at least one of the following:

a pharmaceutically acceptable auxiliary;

a pharmaceutically acceptable preservative;

a pharmaceutically acceptable excipient; or

any combination thereof.

19. The pharmaceutical composition according to claim 17 , wherein the pharmaceutical composition is in the form of a tablet, a capsule, a cachet, a powder, a granule, a solution, a suspension, an emulsion, a bolus, a lozenge, a suppository, a pessary, a tampon, a cream, a gel, a paste, a foam, a spray, an aerosol, a microcapsule, a liposome, a transdermal patch, a pastille, a paste, or a mouthwash.

20. A compound of the formula

or a stereoisomer thereof, or a salt thereof, wherein B is selected from

21. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to claim 20 .

22. The pharmaceutical composition according to claim 21 , further comprising at least one of the following:

a pharmaceutically acceptable auxiliary;

a pharmaceutically acceptable preservative;

a pharmaceutically acceptable excipient; or

any combination thereof.

23. The pharmaceutical composition according to claim 21 , wherein the pharmaceutical composition is in the form of a tablet, a capsule, a cachet, a powder, a granule, a solution, a suspension, an emulsion, a bolus, a lozenge, a suppository, a pessary, a tampon, a cream, a gel, a paste, a foam, a spray, an aerosol, a microcapsule, a liposome, a transdermal patch, a pastille, a paste, or a mouthwash.

24. A compound of the formula

or a stereoisomer thereof, or a salt thereof, wherein:

A is selected from

B is selected from

C is selected from

25. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to claim 24 .

26. The pharmaceutical composition according to claim 25 , further comprising at least one of the following:

a pharmaceutically acceptable auxiliary;

a pharmaceutically acceptable preservative;

a pharmaceutically acceptable excipient; or

any combination thereof.

27. The pharmaceutical composition according to claim 25 , wherein the pharmaceutical composition is in the form of a tablet, a capsule, a cachet, a powder, a granule, a solution, a suspension, an emulsion, a bolus, a lozenge, a suppository, a pessary, a tampon, a cream, a gel, a paste, a foam, a spray, an aerosol, a microcapsule, a liposome, a transdermal patch, a pastille, a paste, or a mouthwash.

28. A compound of the formula

or a stereoisomer thereof, or a salt thereof, wherein:

A is selected from

B is selected from

C is selected from

 with the proviso that when A

 and B is

 then C is not

29. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of the formula

or a stereoisomer thereof, or a salt thereof, wherein:

A is selected from

B is selected from

C is selected from

30. The pharmaceutical composition according to claim 29 , further comprising at least one of the following:

a pharmaceutically acceptable auxiliary;

a pharmaceutically acceptable preservative;

a pharmaceutically acceptable excipient; or

any combination thereof.

31. The pharmaceutical composition according to claim 29 , wherein the pharmaceutical composition is in the form of a tablet, a capsule, a cachet, a powder, a granule, a solution, a suspension, an emulsion, a bolus, a lozenge, a suppository, a pessary, a tampon, a cream, a gel, a paste, a foam, a spray, an aerosol, a microcapsule, a liposome, a transdermal patch, a pastille, a paste, or a mouthwash.

32. A compound of the formula

or a stereoisomer thereof, or a salt thereof, wherein:

A is selected from

B is selected from

C is selected from

 with the proviso that when A is

 and B is

 then C is not

33. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of the formula

or a stereoisomer thereof, or a salt thereof, wherein:

A is selected from

B is selected from

C is selected from

34. The pharmaceutical composition according to claim 33 , further comprising at least one of the following:

a pharmaceutically acceptable auxiliary;

a pharmaceutically acceptable preservative;

a pharmaceutically acceptable excipient; or

any combination thereof.

35. The pharmaceutical composition according to claim 33 , wherein the pharmaceutical composition is in the form of a tablet, a capsule, a cachet, a powder, a granule, a solution, a suspension, an emulsion, a bolus, a lozenge, a suppository, a pessary, a tampon, a cream, a gel, a paste, a foam, a spray, an aerosol, a microcapsule, a liposome, a transdermal patch, a pastille, a paste, or a mouthwash.

36. A compound of the formula

or a stereoisomer thereof, or a salt thereof, wherein:

A is selected from

B is selected from

C is selected from

 with the proviso that when A is

 and B is

 then C is not

37. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of the formula

or a stereoisomer thereof, or a salt thereof, wherein:

A is selected from

B is selected from

C is selected from

38. The pharmaceutical composition according to claim 37 , further comprising at least one of the following:

a pharmaceutically acceptable auxiliary;

a pharmaceutically acceptable preservative;

a pharmaceutically acceptable excipient; or

any combination thereof.

39. The pharmaceutical composition according to claim 37 , wherein the pharmaceutical composition is in the form of a tablet, a capsule, a cachet, a powder, a granule, a solution, a suspension, an emulsion, a bolus, a lozenge, a suppository, a pessary, a tampon, a cream, a gel, a paste, a foam, a spray, an aerosol, a microcapsule, a liposome, a transdermal patch, a pastille, a paste, or a mouthwash.

40. A compound of the formula

or a stereoisomer thereof, or a salt thereof, wherein

A is selected from

B is selected from

C is selected from

 with the proviso that when A is

 and B is

 then C is not

41. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of the formula

or a stereoisomer thereof, or a salt thereof, wherein

A is selected from

B is selected from

C is selected from

42. The pharmaceutical composition according to claim 41 , further comprising at least one of the following:

a pharmaceutically acceptable auxiliary;

a pharmaceutically acceptable preservative;

a pharmaceutically acceptable excipient; or

any combination thereof.

43. The pharmaceutical composition according to claim 41 , wherein the pharmaceutical composition is in the form of a tablet, a capsule, a cachet, a powder, a granule, a solution, a suspension, an emulsion, a bolus, a lozenge, a suppository, a pessary, a tampon, a cream, a gel, a paste, a foam, a spray, an aerosol, a microcapsule, a liposome, a transdermal patch, a pastille, a paste, or a mouthwash.

44. A compound of the formula

or a stereoisomer thereof, or a salt thereof, wherein:

A is selected from

B is selected from

C is selected from

45. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to claim 44 .

46. The pharmaceutical composition according to claim 45 , further comprising at least one of the following:

a pharmaceutically acceptable auxiliary;

a pharmaceutically acceptable preservative;

a pharmaceutically acceptable excipient; or

any combination thereof.

47. The pharmaceutical composition according to claim 45 , wherein the pharmaceutical composition is in the form of a tablet, a capsule, a cachet, a powder, a granule, a solution, a suspension, an emulsion, a bolus, a lozenge, a suppository, a pessary, a tampon, a cream, a gel, a paste, a foam, a spray, an aerosol, a microcapsule, a liposome, a transdermal patch, a pastille, a paste, or a mouthwash.

48. A compound of the formula

or a stereoisomer thereof, or a salt thereof, wherein:

A is independently selected from Cl, OH

B is independently selected from

C is independently selected from

 with the proviso that when A is

 and B is

 then C is not

49. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of the formula

or a stereoisomer thereof, or a salt thereof, wherein:

A is independently selected from Cl, OH,

B is independently selected from

C is independently selected from

50. The pharmaceutical composition according to claim 49 , further comprising at least one of the following:

a pharmaceutically acceptable auxiliary;

a pharmaceutically acceptable preservative;

a pharmaceutically acceptable excipient; or

any combination thereof.

51. The pharmaceutical composition according to claim 49 , wherein the pharmaceutical composition is in the form of a tablet, a capsule, a cachet, a powder, a granule, a solution, a suspension, an emulsion, a bolus, a lozenge, a suppository, a pessary, a tampon, a cream, a gel, a paste, a foam, a spray, an aerosol, a microcapsule, a liposome, a transdermal patch, a pastille, a paste, or a mouthwash.

52. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of the formula

or a stereoisomer thereof, or a salt thereof, wherein:

A is independently selected from

B is independently selected from

C is independently selected from

53. The pharmaceutical composition according to claim 52 , further comprising at least one of the following:

a pharmaceutically acceptable auxiliary;

a pharmaceutically acceptable preservative;

a pharmaceutically acceptable excipient; or

any combination thereof.

54. The pharmaceutical composition according to claim 52 , wherein the pharmaceutical composition is in the form of a tablet, a capsule, a cachet, a powder, a granule, a solution, a suspension, an emulsion, a bolus, a lozenge, a suppository, a pessary, a tampon, a cream, a gel, a paste, a foam, a spray, an aerosol, a microcapsule, a liposome, a transdermal patch, a pastille, a paste, or a mouthwash.

55. A compound of the formula:

or a stereoisomer thereof; or a salt thereof;

wherein:

R 1 is in each occurrence independently selected from —H; linear or branched alkyl with up to 10 carbon atoms; cycloalkyl with up to 10 carbon atoms; or aryl;

E is CH or N;

n is an integer from 0 to 3;

X 1 is selected from —H, m-F, m-Cl, m-Br, m-I, m-CN, m-NO 2 , m-SO 2 R 1 , or m-SO 2 OR 1 , or X 1 and X 2 together is a fused benzene or pyridine ring;

X 2 is selected from —H, o-Cl, o-Br, p-OR 1 , p-SR 1 , p-NR 1 2 , p-F, p-Cl, p-Br, p-CF 3 , p-C(O)OR 1 , p-OM, or p-SM, wherein M is selected from Li, Na, K, Mg, or Ca;

A is NR 1 and Y 1 is selected from cycloalkyl with up to 10 carbon atoms, linear or branched alkyl with up to 10 carbon atoms, or

 or AY 1 is selected from a halogen,

DY 2 is a halogen, or D is NR 1 and Y 2 is selected from

 (CHR 1 ) x NR 1 2 , wherein x is an integer from 1 to 6.

56. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to claim 55 .

57. The pharmaceutical composition as claimed in claim 56 , further comprising at least one of the following:

a pharmaceutically acceptable auxiliary;

a pharmaceutically acceptable preservative;

a pharmaceutically acceptable excipient; or

any combination thereof.

58. The pharmaceutical composition as claimed in claim 56 , wherein the pharmaceutical composition is in the form of a tablet, a capsule, a cachet, a powder, a granule, a solution, a suspension, an emulsion, a bolus, a lozenge, a suppository, a pessary, a tampon, a cream, a gel, a paste, a foam, a spray, an aerosol, a microcapsule, a liposome, a transdermal patch, a pastille, a paste, or a mouthwash.

59. A compound of the formula:

or a stereoisomer thereof; or a salt thereof;

wherein:

R 1 is in each occurrence independently selected from —H; linear or branched alkyl with up to 10 carbon atoms; cycloalkyl with up to 10 carbon atoms; or aryl;

E is CH or N;

n is an integer from 0 to 3;

X 1 is selected from —H, m-F, m-Cl, m-Br, m-I, m-CN, m-NO 2 , m-SO 2 R1, or m-SO 2 OR 1 , or X 1 and X 2 together is a fused benzene or pyridine ring;

X 2 is selected from —H, o-Cl, o-Br, p-OR 1 , p-SR 1 , p-NR 1 2 , p-F, p-Cl, p-Br, p-CF 3 , p-C(O)OR 1 , p-OM, or p-SM, wherein M is selected from Li, Na, K, Mg, or Ca;

A is selected from NR 1 or O, wherein Y 1 is selected from cycloalkyl with up to 10 carbon atoms, linear or branched alkyl with up to 10 carbon atoms, or

 when A is NR 1 , and wherein Y 1 is selected from R 1 or CH 2 R 1 when A is O; or AY 1 is selected from a halogen,

DY 2 is a halogen, or D is NR 1 and Y 2 is selected from

60. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to claim 59 .

61. The pharmaceutical composition as claimed in claim 60 , further comprising at least one of the following:

a pharmaceutically acceptable auxiliary;

a pharmaceutically acceptable preservative;

a pharmaceutically acceptable excipient; or

any combination thereof.

62. The pharmaceutical composition as claimed in claim 60 , wherein the pharmaceutical composition is in the form of a tablet, a capsule, a cachet, a powder, a granule, a solution, a suspension, an emulsion, a bolus, a lozenge, a suppository, a pessary, a tampon, a cream, a gel, a paste, a foam, a spray, an aerosol, a microcapsule, a liposome, a transdermal patch, a pastille, a paste, or a mouthwash.

63. A compound of the formula:

or a stereoisomer thereof; or a salt thereof;

wherein:

R 1 is in each occurrence independently selected from —H; linear or branched alkyl with up to 10 carbon atoms; cycloalkyl with up to 10 carbon atoms; aryl; or (CH 2 ) x CN, wherein x is an integer from 0 to 6;

E is CH or N;

n is an integer from 0 to 3;

X 1 is selected from —H, m-F, m-Cl, m-Br, m-I, m-CN, m-NO 2 , m-SO 2 R 1 , m-SO 2 R 1 , m-NC(O)R 1 , or o-F, or X 1 and X 2 together is a fused benzene, pyridine, or dioxane ring;

X 2 is selected from —H, o-Cl, o-Br, o-CF 3 , o-R 1 , p-OR 1 , p-SR 1 , p-NR 1 2 , p-F, p-Cl, p-Br, p-CF 3 , p-CN, p-C(O)OR 1 , p-NC(O)R 1 , p-(4-morpholinyl), or p-(4-methyl-1-piperazinyl);

AY 1 is a halogen, or A is NR 1 and Y 1 is selected from cycloalkyl with up to 10 carbon atoms, cycloalkyl with up to 10 carbon atoms substituted with R 1 , linear or branched alkyl with up to 10 carbon atoms, CH 2 R 1 , (CHR 1 ) y OR 1 wherein y is an integer from 1 to 6,

 or A is O and Y 1 is selected from (CHR 1 ) y OR 1 , wherein y is an integer from 1 to 6, or

 or AY 1 together are

 wherein x is an integer from 3 to 5; and

DY 2 is a halogen, or D is NR 1 and Y 2 is selected from

 cycloalkyl with up to 10 carbon atoms, cycloalkyl with up to 10 carbon atoms substituted with R 1 , linear or branched alkyl with up to 10 carbon atoms, CH 2 R 1 ,

 wherein x is an integer from 3 to 5,

 wherein z is an integer from 1 to 6,

 wherein x is an integer from 3 to 5,

 or NY 2 R 1 together is selected from

 wherein Z 2 is selected from R 1 , C(O)R 1 ′, C(O)OR 1 , pyridinyl, aryl,

 wherein q is an integer from 0 to 6.

64. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to claim 63 .

65. The pharmaceutical composition as claimed in claim 64 , further comprising at least one of the following:

a pharmaceutically acceptable auxiliary;

a pharmaceutically acceptable preservative;

a pharmaceutically acceptable excipient; or

any combination thereof.

66. The pharmaceutical composition as claimed in claim 64 , wherein the pharmaceutical composition is in the form of a tablet, a capsule, a cachet, a powder, a granule, a solution, a suspension, an emulsion, a bolus, a lozenge, a suppository, a pessary, a tampon, a cream, a gel, a paste, a foam, a spray, an aerosol, a microcapsule, a liposome, a transdermal patch, a pastille, a paste, or a mouthwash.

67. A compound of the formula:

or a stereoisomer thereof or a salt thereof;

wherein:

R 1 is in each occurrence independently selected from —H; linear or branched alkyl with up to 10 carbon atoms; cycloalkyl with up to 10 carbon atoms; aryl; or (CH 2 ) x CN, wherein x is an integer from 0 to 6;

E is CH or N;

n is an integer from 0 to 3;

X 1 is selected from —H, m-F, m-Cl, m-Br, m-I, m-CN, m-NO 2 , m-SO 2 R 1 , m-SO 2 OR 1 , m-NC(O)R 1 , or o-F, or X 1 and X 2 together is a fused benzene, pyridine, or dioxane ring;

X 2 is selected from —H, o-Cl, o-Br, o-CF 3 , o-R 1 , p-OR 1 , p-SR 1 , p-NR 1 2 , p-F, p-Cl, p-Br, p-CF 3 , p-CN, p-C(O)OR 1 , p-NC(O)R 1 , p-(4-morpholinyl), or p-(4-methyl-1-piperazinyl);

AY 1 is a halogen, or A is NR 1 or O and Y 1 is selected from cycloalkyl with up to 10 carbon atoms, cycloalkyl with up to 10 carbon atoms substituted with R 1 , linear or branched alkyl with up to 10 carbon atoms, CH 2 R 1 , (CHR 1 ) y OR 1 , wherein y is an integer from 1 to 6,

 or AY 1 together are

 wherein x is an integer from 3 to 5; and

DY 2 is a halogen, or D is NR 1 and Y 2 is selected from

 cycloalkyl with up to 10 carbon atoms, cycloalkyl with up to 10 carbon atoms substituted with R 1 , linear or branched alkyl with up to 10 carbon atoms, CH 2 R 1 ,

 wherein x is an integer from 3 to 5,

 (CHR 1 ) z NR 1 2 , wherein z is an integer from 1 to 6 and wherein no more than one R 1 group of NR 1 2 is alkyl,

 wherein x is an integer from 3 to 5,

 or NY 2 R 1 together is selected from

 wherein Z 2 is selected from R 1 , C(O)R 1 , C(O)OR 1 , pyridinyl, aryl,

 or

 wherein q is an integer from 0 to 6.

68. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to claim 67 .

69. The pharmaceutical composition as claimed in claim 68 , further comprising at least one of the following:

a pharmaceutically acceptable auxiliary;

a pharmaceutically acceptable preservative;

a pharmaceutically acceptable excipient; or

any combination thereof.

70. The pharmaceutical composition as claimed in claim 68 , wherein the pharmaceutical composition is in the form of a tablet, a capsule, a cachet, a powder, a granule, a solution, a suspension, an emulsion, a bolus, a lozenge, a suppository, a pessary, a tampon, a cream, a gel, a paste, a foam, a spray, an aerosol, a microcapsule, a liposome, a transdermal patch, a pastille, a paste, or a mouthwash.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE ADDRESS OF THE RECEIVING PARTY AS LISTED ON THE PATENT ASSIGNMENT COVER SHEET ATTACHED HERETO AND PREVIOUSLY RECORDED ON REEL 023985 FRAME 0502. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECT ADDRESS OF THE RECEIVING PARTY IS 7-1-27, AMEERPET, HYDERABAD-500016, INDIA.. Recorded Jul 6, 2010
From: REDDY US THERAPEUTICS, INC.
To: DR. REDDY'S LABORATORIES LTD.
Reel/Frame 024630/0384 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 25, 2010
From: REDDY US THERAPEUTICS, INC.
To: DR. REDDY'S LABORATORIES LTD.
Reel/Frame 023985/0502 →